|
JP6453212B2
(ja)
|
2012-07-13 |
2019-01-16 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
キラル制御
|
|
SG11201500239VA
(en)
|
2012-07-13 |
2015-03-30 |
Wave Life Sciences Japan |
Asymmetric auxiliary group
|
|
ES2917473T3
(es)
|
2014-01-16 |
2022-07-08 |
Wave Life Sciences Ltd |
Diseño quiral
|
|
CN108135921B
(zh)
|
2015-07-22 |
2023-10-17 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
CA3015823A1
(en)
|
2016-03-13 |
2017-09-21 |
Wave Life Sciences Ltd. |
Compositions and methods for phosphoramidite and oligonucleotide synthesis
|
|
CN109562122A
(zh)
|
2016-06-03 |
2019-04-02 |
波涛生命科学有限公司 |
寡核苷酸、组合物及其方法
|
|
EP3475424A1
(en)
|
2016-06-22 |
2019-05-01 |
ProQR Therapeutics II B.V. |
Single-stranded rna-editing oligonucleotides
|
|
US10941402B2
(en)
|
2016-09-01 |
2021-03-09 |
Proqr Therapeutics Ii B.V. |
Chemically modified single-stranded RNA-editing oligonucleotides
|
|
MA46905A
(fr)
|
2016-11-23 |
2019-10-02 |
Wave Life Sciences Ltd |
Compositions et procédés de synthèse de phosphoramidites et d'oligonucléotides
|
|
US11597927B2
(en)
|
2017-06-02 |
2023-03-07 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
US11603532B2
(en)
|
2017-06-02 |
2023-03-14 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
US11718638B2
(en)
|
2017-06-21 |
2023-08-08 |
Wave Life Sciences Ltd. |
Compounds, compositions and methods for synthesis
|
|
TW201920672A
(zh)
|
2017-08-08 |
2019-06-01 |
新加坡商波濤生命科學有限公司 |
寡核苷酸組合物及其使用方法
|
|
CN111108096A
(zh)
|
2017-09-18 |
2020-05-05 |
波涛生命科学有限公司 |
寡核苷酸制备技术
|
|
EP3694530A4
(en)
|
2017-10-12 |
2021-06-30 |
Wave Life Sciences Ltd. |
COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
|
|
AU2019218987B2
(en)
|
2018-02-12 |
2025-04-24 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
IL277889B2
(en)
|
2018-04-12 |
2025-01-01 |
Wave Life Sciences Ltd |
Oligonucleotide preparations and methods of using them
|
|
EP3790596A4
(en)
|
2018-05-11 |
2022-04-06 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
CN113748116A
(zh)
|
2019-03-20 |
2021-12-03 |
波涛生命科学有限公司 |
可用于寡核苷酸制备的技术
|
|
KR20220070324A
(ko)
*
|
2019-10-06 |
2022-05-30 |
웨이브 라이프 사이언시스 리미티드 |
올리고뉴클레오티드 조성물 및 이의 이용 방법
|
|
CA3236136A1
(en)
*
|
2021-10-27 |
2023-05-04 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
US20250154504A1
(en)
|
2022-02-14 |
2025-05-15 |
Proqr Therapeutics Ii B.V. |
Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
|
|
EP4555086A1
(en)
|
2022-07-15 |
2025-05-21 |
ProQR Therapeutics II B.V. |
Oligonucleotides for adar-mediated rna editing and use thereof
|
|
WO2024013360A1
(en)
|
2022-07-15 |
2024-01-18 |
Proqr Therapeutics Ii B.V. |
Chemically modified oligonucleotides for adar-mediated rna editing
|
|
GB202215614D0
(en)
|
2022-10-21 |
2022-12-07 |
Proqr Therapeutics Ii Bv |
Heteroduplex rna editing oligonucleotide complexes
|
|
AR131145A1
(es)
|
2022-11-24 |
2025-02-19 |
Proqr Therapeutics Ii Bv |
Oligonucleótidos antisentido para el tratamiento de hemocromatosis hfe hereditaria
|
|
GB202218090D0
(en)
|
2022-12-01 |
2023-01-18 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
|
|
CA3276262A1
(en)
|
2022-12-09 |
2024-06-13 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
GB202300865D0
(en)
|
2023-01-20 |
2023-03-08 |
Proqr Therapeutics Ii Bv |
Delivery of oligonucleotides
|
|
EP4669753A1
(en)
|
2023-02-20 |
2025-12-31 |
ProQR Therapeutics II B.V. |
Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
|
|
GB202304363D0
(en)
|
2023-03-24 |
2023-05-10 |
Proqr Therapeutics Ii Bv |
Chemically modified antisense oligonucleotides for use in RNA editing
|
|
WO2024206175A1
(en)
|
2023-03-24 |
2024-10-03 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurological disorders
|
|
AU2024246572A1
(en)
|
2023-03-27 |
2025-10-30 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of liver disease
|
|
WO2024256620A1
(en)
|
2023-06-16 |
2024-12-19 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurodegenerative disease
|
|
WO2025051946A1
(en)
|
2023-09-07 |
2025-03-13 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of metabolic disorders
|
|
WO2025104239A1
(en)
|
2023-11-16 |
2025-05-22 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of classic galactosemia
|
|
WO2025132708A1
(en)
|
2023-12-20 |
2025-06-26 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of huntington's disease
|
|
GB202404661D0
(en)
|
2024-04-02 |
2024-05-15 |
Proqr Therapeutics Ii Bv |
Antisense oligoncleotides for the treatment of liver disease
|
|
WO2025213142A2
(en)
*
|
2024-04-05 |
2025-10-09 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
WO2025224230A1
(en)
|
2024-04-25 |
2025-10-30 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of fatty liver disease
|
|
GB202410081D0
(en)
|
2024-07-11 |
2024-08-28 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
WO2026022136A1
(en)
|
2024-07-23 |
2026-01-29 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of metabolic disorders
|
|
WO2026060374A2
(en)
|
2024-09-16 |
2026-03-19 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurological disorders
|
|
WO2026068781A1
(en)
|
2024-09-30 |
2026-04-02 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of liver disease
|